Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature
- 1 June 2005
- journal article
- case report
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 97 (3), 924-927
- https://doi.org/10.1016/j.ygyno.2004.10.031
Abstract
Intrauterine progesterone therapy potentially provides a simple alternative treatment for women with Stage I Grade I endometrial cancers who are at high risk for surgery. The case histories of four women with early endometrial cancer primarily treated with levonorgestrel intrauterine system (Mirena) are reported and the literature reviewed. Four women had Stage I grade 1 endometrial adenocarcinoma with positive progesterone receptor. All were assessed to be in American Society of anaesthesiologists risk class IV. After insertion of mirena intrauterine system, one woman (25%) had complete histological regression of disease within 6 months. One of three women who did not respond to treatment subsequently had a vaginal hysterectomy, which showed endometrial cancer with superficial myometrial invasion. This report raises doubts about the effectiveness of intrauterine progesterone therapy as a definitive alternative for the treatment of early endometrial cancer.Keywords
This publication has 9 references indexed in Scilit:
- Endometrial Adenocarcinoma Following the Insertion of a Mirena IUCDGynecologic Oncology, 2002
- Intrauterine progesterone treatment of early endometrial cancerAmerican Journal of Obstetrics and Gynecology, 2002
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Role of Exogenous and Endogenous Hormones in Endometrial CancerAnnals of the New York Academy of Sciences, 2001
- Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcomeCancer Letters, 2001
- The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasiaCancer, 2000
- Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology GroupJournal of Clinical Oncology, 1999
- Complications of HysterectomyClinical Obstetrics and Gynecology, 1997
- Progestin alone as primary treatment of endometrial carcinoma in premenopausal womenCancer, 1997